New studies and experiments are being run on the experimental anti-thrombotic medication Vorapaxar by researchers to thoroughly study the effects of the medication, good as well as bad ones.
On adding the medication to a standard treatment being given to patients who have a medical history of cardiovascular events or disease, the researchers noticed that the combined effect reduced the number of cardiovascular events but, on the other hand, the treatment showed some side effects like increased bleeding and intracranial hemorrhage.
The study deeply revealed that the condition called ICH (Intracranial Hemorrhage) was not present in those patients, who never suffered any stroke.
The researcher's main aim during the TRA-2P trial (Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) that they ran during the TIMI 50 study was to clearly study the safety and efficacy of the experimental drug Vorapaxar. Many more studies are ongoing on the medication, some of which are testing the drug against acute coronary syndrome chest pain that is caused by coronary artery disease.
The trial was organized by Merck & Co., Inc., a famous name in the pharmaceutical industry and also the owner of the medication Vorapaxar.
Another human study in which the medication was added to thienopyridine, aspirin or both standard care to check its effects showed that the combination can help in lessening the risks of composite cardiovascular death, stroke, heart attack or an urgent coronary revascularization.
Regarding the situation, Merck & Co., Inc., wrote in its website: "This is the first time that an anti-thrombotic medicine added to the standard of care, including aspirin, has been shown to provide an additional, significant reduction in cardiovascular events in the secondary prevention setting".